Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Diabetes remains the commonest cause of treated kidney failure in Australia and is a common comorbidity among those with CKD. We aimed to determine the rates of kidney failure and death without kidney failure among patients with CKD and Diabetes receiving kidney specialist care in a large Australian State.
The data source was the CKD-Queensland Registry, which enrolled patients with CKD receiving outpatient kidney specialist care at one of 12 public hospitals in the state of Queensland, Australia.
Patients with diabetes who were first consented to enrol in the CKD Queensland registry between its inception in 2011 and 31/12/2016 were followed until the occurrence of kidney failure, death without kidney failure, discharge from care, movement interstate or overseas, transfer of care to the private sector, loss to follow-up or the study censor date of 31/12/2023. Patients who transferred care between participating hospitals continued their follow-up in linear fashion.
Kidney failure was defined as either commencement of kidney replacement therapy (dialysis or transplant) or at least 2 consecutive CKD-epi eGFR values <10ml/min/1.73m2 in those who did not commence kidney replacement therapy during the course of follow-up.
The cohort comprised 2355 patients with mean age 67.8y (SD 12.2), of whom 56% were male. Median eGFR at enrolment was 34ml/min/1.73m2 and over two-thirds had eGFR < 45ml/min/1.73m2. 47% of patients had urine ACR ≥30mg/mmol or protein:creatinine ratio ≥50mg/mmol at enrolment whilst 15% met criteria for nephrotic range proteinuria at enrolment (ACR ≥220mg/mmol or protein:creatinine ≥300mg/mmol).
RAAS blockers (ACE-inhibitor, Angiotensin receptor blocker, Mineralocorticoid antagonist or any combination of the three) were prescribed in 80% at enrolment and the prescription rate remained similar at 77% when assessed again in those who were still alive without kidney failure on 1/1/2022. In contrast, only 9.3% were prescribed SGLT-2 inhibitors and 10.1% were prescribed GLP-1 agonist at the same time point.
Pre-enrolment burden of cardiovascular disease was high – 37% of patients had a prior history of major adverse cardiovascular event at enrolment.
Over the follow-up period of 11252 patient years (median follow-up 3.89 years), 548 patients (23%) developed kidney failure whilst 798 patients (34%) died without kidney failure. The incidence rate ratio of death without kidney failure to kidney failure was 1.45.
Both kidney failure and death without kidney failure were common outcomes, occurring in >50% of the cohort by the end of follow-up.
This patient cohort was characterised by a high prevalence of advanced kidney disease at enrolment so was expected to be at particular risk of kidney failure. Despite an expanded definition of kidney failure (to include patients who chose not to have kidney replacement therapy and those who could have but had not yet commenced such therapy), death without kidney failure remained the more common outcome.
Whilst RAAS blocker prescription rates were high throughout, SGLT-2 inhibitor and GLP-1 agonist prescription rates were still low reflecting the relatively recent pharmaceutical benefits funding arrangements for these agents at the time.
